Healthcare entity
All 1 tracked stories fall under one category: market-trends. PD-1 is most often covered alongside ASCO 2026, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention PD-1, all published on June 15, 2026.
Last mentioned: Jun 15, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: market-trends. PD-1 is most often covered alongside ASCO 2026, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention PD-1, all published on June 15, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 7 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering PD-1. Shared-story counts are live from our verified record — not editorial picks.
CStone's CS2009, a first-in-class trispecific antibody, has demonstrated at ASCO 2026 that it can be dosed continuously while maintaining a safety profile similar to PD-1 monotherapy. This could transform treatment for cancer patients who previously had to stop CTLA-4 therapies early due to severe side effects.
PD-1 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
